Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Total Current Liabilities
Apontis Pharma AG
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
Apontis Pharma AG
XETRA:APPH
|
Total Current Liabilities
€11.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
ATAI Life Sciences NV
NASDAQ:ATAI
|
Total Current Liabilities
$20.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Bayer AG
XETRA:BAYN
|
Total Current Liabilities
€29B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
![]() |
Merck KGaA
XETRA:MRK
|
Total Current Liabilities
€11.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
![]() |
Dermapharm Holding SE
XETRA:DMP
|
Total Current Liabilities
€374.9m
|
CAGR 3-Years
33%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
![]() |
PharmaSGP Holding SE
XETRA:PSG
|
Total Current Liabilities
€24.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Total Current Liabilities?
Total Current Liabilities
11.3m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Total Current Liabilities amounts to 11.3m EUR.
What is Apontis Pharma AG's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
38%
Over the last year, the Total Current Liabilities growth was 90%. The average annual Total Current Liabilities growth rates for Apontis Pharma AG have been 38% over the past three years .